Jsmc-10357

DOOR-TO-BALLOON TIME AND CARDIOVASCULAR OUTCOMES IN PATIENTS WITH ST-ELEVATION MYOCARDIAL INFARCTION TREATED WITH PRIMARY PERCUTANEOUS INTERVENTION

Dara M. Mohialdeen a, Mohammed M. Arif a, and Swara A. Mawlood b

a College of Medicine, University of Sulaimani, Kurdistan Region, Iraq 

b Sulaimani Cardiac Hospital, Sulaimani, Kurdistan Region, Iraq

Submitted: 7/9/2021; Accepted: 9/3/2022; Published: 21/6/2022

DOI Link: https://doi.org/10.17656/jsmc.10357 

ABSTRACT 

Background 

Primary percutaneous coronary intervention (PCI) is the preferred reperfusion strategy in patients with ST-elevation myocardial infarction (STEMI) within 12 hours of symptom onset, provided it can be performed expeditiously (i.e., 120 min from STEMI diagnosis) by an experienced team. A professional team includes not only interventional cardiologists but also skilled support staff. Lower mortality rates among patients undergoing primary PCI are observed in centres with a high volume of PCI procedures. In addition, door-to-balloon time became an indicator of the quality of care in STEMI patients treated with primary PCI.

Objectives 

To evaluate the impact of door-to-balloon time delay on cardiovascular outcomes in patients with STEMI. 

Methods

Prospective cohort study of door-to-balloon time (DTB) delay and adverse cardiovascular outcomes in patients with STEMI treated with primary PCI.

Results

About 65% (n=131) of patients were free from adverse outcomes with a Mean door-to-balloon time of 92 minutes vs adverse effects (left ventricular dysfunction or angina) happened in 26% (n=52) with a mean door-to-balloon time of 168 minutes and death in 8% (n=16) with a mean time of 114 minutes (P=0.001). Similar results were found with symptom onset-to-balloon time, no adverse outcomes with a mean symptom onset-to-balloon time of 11.98 hours compared to 22 hours with adverse effects and deaths;( p=0.004.)

Conclusion

Any delay in door-to-balloon time or symptom onset-to-balloon time in patients with ST-elevation myocardial infarction is associated with higher morbidity and mortality rate.

KEYWORDS

Door-to-balloon time, Primary percutaneous coronary intervention, ST-segment elevation, Myocardial infarction.

References 

1. O’Gara PT, Kushner FG, Ascheim DD, Casey Jr DE, Chung MK, de Lemos JA, et al.  ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the American College of Emergency Physicians and Society for Cardiovascular Angiography and Interventions. Catheter Cardiovasc Interv. 2013; 82(1): E1–27.

2. Boersma E, Primary Coronary Angioplasty vs Thrombolysis Group. Does time matter? A pooled randomized clinical trial analysis compares primary percutaneous coronary intervention and in-hospital fibrinolysis in acute myocardial infarction patients. Eur Heart J 2006; 27(7):779–788.

3. Boersma E, Maas ACP, Deckers JW, Simoons ML. Early thrombolytic treatment in acute myocardial infarction: a reappraisal of the golden hour. Lancet 1996; 348(9030):771–775.

4. Mun K. Hong. Recent Advances in the Treatment of ST-Segment Elevation Myocardial Infarction. Scientifica Volume 2012 (2012), Article ID 683683.

5. Fordyce CB, Al-Khalidi HR, Jollis JG, Roettig ML, Gu J, Bagai A, et al. Association of rapid care process implementation on reperfusion times across multiple ST-segment-elevation myocardial infarction networks. Circ Cardiovasc Interv 2017; 10(1):e004061.

6. Stowens JC, Sonnad SS, Rosenbaum RA. Using EMS dispatch to trigger STEMI alerts decreases door-to-balloon times. West J Emerg Med 2015; 16(3):472–480.

7. Squire BT, Tamayo-Sarver JH, Rashi P, Koenig W, Niemann JT. Prehospital cardiac catheterization lab activation affects door-to-balloon time, mortality, and false-positive activation. Prehosp Emerg Care 2014; 18(1):1–8.

8. Nallamothu BK, Normand SL, Wang Y, Hofer TP, Brush JE, Messenger JC, et al. Relation between door-to-balloon times and mortality after primary percutaneous coronary intervention over time: a retrospective study. Lancet 2015; 385(9973):1114–1122.

9. Zijlstra F, Hoorntje JC, de Boer MJ, Reiffers S, Miedema K, Ottervanger JP, et al. Long-term benefit of primary angioplasty as compared with thrombolytic therapy for acute myocardial infarction. N Engl J Med 1999; 341(19):1413–1419.

10. Kastrati A, Dibra A, Spaulding C, Laarman GJ, Menichelli M, Valgimigli M, et al. Meta-analysis of randomized trials on drug-eluting stents vs bare-metal stents in patients with acute myocardial infarction. Eur Heart J 2007; 28(22):2706–2713.

11. Peter B. Berger, Stephen G. Ellis, David R. Holmes Jr, Christopher B. Granger, Douglas A. Criger, Amadeo Betriu, et al. Relationship between delay in performing direct coronary angioplasty and early clinical outcome in patients with acute myocardial infarction: results from the Global Use of Strategies to Open Occluded Arteries in Acute Coronary Syndromes (GUSTO-IIb) trial Circulation, 1999;100(1): 14-20.

12. McNamara RL, Wang Y, Herrin J, Curtis JP, Bradley EH, Magid DJ, et al. Effect of door-to-balloon time on mortality in patients with ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2006; 47(11):2180–2186. 

13. De Luca G, Suryapranata H, Zijlstra F, van‘t Hof AW, Hoorntje JC, Gosselink AT, et al. Symptom-onset-to-balloon time and mortality in patients with acute myocardial infarction treated by primary angioplasty. J Am Coll Cardiol. 2003; 42(6):991–997.

14. Shiomi H, Nakagawa Y, Morimoto T, Furukawa Y, Nakano A, Shirai S, et al. Association of onset to balloon and door to balloon time with long-term clinical outcome in patients with ST-elevation acute myocardial infarction having primary percutaneous coronary intervention: an observational study. BMJ. 2012; 344:e3257.

15. Brodie BR, Gersh BJ, Stuckey T, Witzenbichler B, Guagliumi G, Peruga JZ, et al. When is door-to-balloon time critical? Analysis from the HORIZONS-AMI (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction) and CADILLAC (Controlled Abciximab and Device Investigation Lower Late Angioplasty Complications) trials. J Am Coll Cardiol. 2010; 56(5):407–413.

Full Text

 © The Authors, published by University of Sulaimani, College of Medicine

This work is licensed under a Creative Commons Attribution 4.0 International License.